Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease

Background. Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series. Pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Antonio Vitale, Virginia Berlengiero, Jurgen Sota, Luisa Ciarcia, Nicola Ricco, Sara Barneschi, Mariam Mourabi, Giuseppe Lopalco, Chiara Marzo, Francesca Bellisai, Florenzo Iannone, Bruno Frediani, Luca Cantarini
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2020/8054961
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1155/2020/8054961

Similar Items